Neoplasms Malignant Clinical Trial
Official title:
Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients: Phase I-II Clinical Trial
Epigallocatechin-3-gallate (EGCG) is a major polyphenol of green tea that possesses a wide variety of actions, such as anti-inflammatory, anti-fibrotic, pro-apoptotic, anti-tumorous, and metabolic effects via modulation of a variety of intracellular signaling cascades. In addition, preclinical studies have also emphasized the antiviral activity of epigallocatechin-3-gallate (EGCG), including SARS-CoV-2. In previous studies, we found that EGCG can prevent and cure radiation-induced normal tissue damage in tumor patients. In clinical studies, we found that EGCG can prevent and treat radiation-induced acute radiation esophagitis, acute radiation skin injury, acute radiation oral mucositis with high safety. Thus, we designed this phase I-II clinical study in order to investigate the possible role of EGCG in the treatment interstitial pneumonia in tumor patients.
In this phase I study, subjects were divided into four dose groups according to the improved Fibonacci method and were given different doses of EGCG to evaluate adverse events. At the same time, the researchers conducted a phase II study of EGCG in tumor patients with interstitial pneumonia. The Phase II study was conducted with a randomized, controlled, placebo dose determined by Phase I. the subjects were divided into two groups (experimental group and placebo group). To observe the effectiveness of EGCG, the researchers will use both clinician assessment and patient self-assessment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04047290 -
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04600206 -
Existential Distress in Patients With Advanced Cancer and Their Caregivers
|
||
| Terminated |
NCT01243762 -
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
|
Phase 1 | |
| Completed |
NCT04728334 -
A Phase 1 Dose Escalation and Expansion Study of AK117
|
Phase 1 | |
| Terminated |
NCT01121588 -
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
|
Phase 1 | |
| Recruiting |
NCT05939687 -
Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection
|
Phase 3 | |
| Recruiting |
NCT06018142 -
Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors
|
||
| Not yet recruiting |
NCT03903848 -
Cancer Survivors Acute Exercise Response 1
|
N/A | |
| Completed |
NCT04637295 -
Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19
|
||
| Completed |
NCT04479579 -
Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
|
Phase 4 | |
| Recruiting |
NCT04230772 -
Clinical Outcomes of NOSES Versus Traditional Robotic-assisted Surgery for Patients With Colorectal Cancer
|
N/A | |
| Not yet recruiting |
NCT05650385 -
A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04616846 -
Thromboembolic Risk Screening in Patients With Cancer and COVID-19
|
N/A | |
| Completed |
NCT04349969 -
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
|
Phase 1 | |
| Recruiting |
NCT04721756 -
Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging
|
Early Phase 1 |